Stoke Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Stoke Therapeutics Inc's ROI in the second quarter of 2026?
Stoke Therapeutics Inc recorded a cumulative net loss of $-208 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -54.4%.

Within the Healthcare sector 495 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3586 to 3677.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	23.98 %	37.63 %	66.14 %	53.13 %	45.9 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	352	426	402	349	371
Return On Investment (TTM)	-54.4 %	-43.87 %	-1.83 %	12.13 %	17.03 %
STOK's Overall Ranking	# 3677	# 3586	# 2421	# 384	# 320
Seq. Investment Change TTM	-1.25 %	2.64 %	12.71 %	8.53 %	9.62 %
Seq. Net Income Change TTM	-	-	-	-22.71 %	4.4 %
Net Income (TTM) in Millions	-208	-170	-7	41	52

STOK Company Profile >> Back to STOK Roi Comparisons >> See Annual STOK Return On Investment

Return On Investment STOK's Ranking
Within:	No.
Industry	# 215
Sector	# 496
Overall	# 3677

Return On Investment Statistics
High	Average	Low
17.88 %	-28.47 %	-55.9 %
(Mar 31 2025)		(Jun 30 2026)

News about Stoke Therapeutics Inc Return on Investment ROI

Innovative Breakthrough Stoke Therapeutics Unveils Zorevunersens Promise to Transform Dravet Syndrome Management,

September 10, 2024

Zorevunersen: A Beacon of Hope for Dravet Syndrome Patients In recent highlights from the 15th European Epilepsy Congress (EEC), Stoke Therapeutics, Inc. (NASDAQ: STOK) unveiled compelling data regarding zorevunersen (STK-001), a transformed approach to treating Dravet syndrome, a severe epileptic disorder that often manifests in infancy. This breakthrough research indicates substantial reductions in the frequency of seizures and noteworthy improvements across various cognitive and behavioral metrics in children affected by this challenging condition, suggesting zorevunersen may indeed offer a disease-modifying effect. The Promise of ZorevunersenDravet syndrome is characterized by frequent and prolonged seizures that can result in developmental delays and significant cognitive impairment as children grow. Current treatment options primarily focus on seizure management rather than addressing the underlying genetic causes of the condition. Stoke Therapeutics has taken a revolutionary step by developing zorevunersen, an antisense oligonucleotide (ASO) aimed at adjusting the protein expression affected by the genetic mutations associated with Dravet syndrome.

Financial Statements
Stoke Therapeutics Inc's II. Quarter Investments	$ 352 Millions	STOK's Balance sheet
Stoke Therapeutics Inc's II. Quarter Income	$ -62 Millions	Quarterly STOK's Income Statement
STOK's Income by Division		See STOK's Income by Division

STOK Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	361	231	198	225	222
Y / Y Investment Growth	55.75 %	17.2 %	-12.08 %	1.33 %	-22.61 %
Net Income in Millions	-7	-89	-105	-101	-86
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-1.91 %	-38.44 %	-53.01 %	-44.98 %	-38.7 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
STOK's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for STOK's Competitors
Subscribers only: Roi for Stoke Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for STOK's Customers

Other Ratios
STOK's Roa	STOK's Inventory Turnover Ratio	STOK's Growth Rates	STOK's Dividend Statistics
	STOK's Profitability Ratios	STOK's Asset Turnover Ratio	STOK's Dividend Growth
STOK's Roe	STOK's Valuation Ratios	STOK's Financial Strength Ratios	STOK's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-09-12T18:57:19+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.